Latest Content

FDA fast tracked ZW191 for platinum-resistant ovarian cancer, aiming to speed development of a potential new option for patients with limited treatments.

Black patients with early-stage lung cancer were less likely to receive curative treatment than White patients, despite all having Medicare coverage, study finds.

Learn about Ductal Carcinoma in Situ (DCIS), its diagnosis, treatment options and side effects. Empower yourself with information to navigate this journey with confidence.

Coverage from NCCN 2026 highlights global care delivery, younger patient needs, survivorship strategies and safer immunotherapy management.

Dr. Brittany Dulmage discusses how management of immune-related side effects can help patients stay on immunotherapy without compromising its effectiveness.

Global efforts in prevention, early detection and collaboration are improving cancer care access, but disparities persist based on where patients live.

Drs. Nunnery and McCann discuss the evolving HER2-positive breast cancer treatment paradigm in the latest episode of “Breast Cancer Briefing.”

FDA approves a PD-L1 test to help identify patients with esophageal or gastroesophageal junction (GEJ) cancer who may benefit from Keytruda.

Dr. Christopher H. Lieu highlights the rising cancer rate in younger adults and the need for more personalized, comprehensive care strategies.

Experts highlight rising cancer rates in younger adults and the need for tailored support, treatment and survivorship care across the continuum.

Hernexeos led to high response rates and disease control in HER2-mutant NSCLC, including patients with brain metastases, with manageable safety.

I struggle sometimes, wondering, “Why me?” and “Why testicular cancer?” Was God telling me something? Maybe to slow down and let him take control. So, I try my best to let go.

Amanda discusses the hidden challenges of chronic GVHD and how advocacy and storytelling help her support others facing similar struggles.